A new system service will roll out this month ahead of big changes starting in September.
InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results